BMI’s technology has the potential to generate vaccines against pathogens for which no effective vaccine exists, improve on the limited protection of previously tried human and veterinary vaccines, and develop therapeutic vaccines that can be given after the onset of disease to supplement the natural response of the immune system.
Many of the programs have cross platforms for both human and veterinary applications and thus offer enhanced synergy for the inputted research and development effort.
BMI is targeting a select mix of human and veterinary diseases that have a spectrum of characteristics that argue in favor of their pursuit in vaccine development such as applicability of its vaccine technology, market size, and worldwide need.
Many of the programs have cross platforms for both human and veterinary applications and thus offer enhanced synergy for the inputted research and development effort.Many yet-to-be-invented vaccines are still needed against some very common, yet debilitating conditions that effect infants through the elderly. Viral and bacaterial pneumonia, the common cold, middle ear infections, diarrhea and vomiting are just a few.
Why are these vaccines still missing?
We'd like to solve that problem.
